Orphan drugs present a number of unique challenges for pharma companies looking to commercialize their products in the US. Collaborating to find patients for trials, improving diagnosis, demonstrating value, engaging with caregivers and developing specialized supply chains are just some of the things to consider.
0
min read
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.